% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Haussmann:164643,
      author       = {Haussmann, Robert and Homeyer, P. and Brandt, Daniel Moritz
                      and Donix, M.},
      title        = {{P}rognostischer und differenzialdiagnostischer
                      {S}tellenwert der {L}iquordiagnostik bei neurodegenerativen
                      {D}emenzerkrankungen.},
      journal      = {Der Nervenarzt},
      volume       = {93},
      number       = {12},
      issn         = {0028-2804},
      address      = {Heidelberg},
      publisher    = {Springer},
      reportid     = {DZNE-2022-01173},
      pages        = {1236-1242},
      year         = {2022},
      abstract     = {Cerebrospinal fluid (CSF) analysis is an important
                      diagnostic tool in the assessment of dementia. For the
                      differentiation of Alzheimer's disease from other etiologies
                      of dementia syndromes, established biological markers could
                      be helpful to confirm a distinctive neuropathology. Whereas
                      negative CSF findings can rule out the majority of primarily
                      neurodegenerative disorders, overlapping biomarker profiles
                      remain a diagnostic challenge. Therefore, it is important to
                      interpret CSF results within a specific clinical context.
                      Furthermore, atypical CSF data can be challenging and
                      require profound knowledge of preanalytics, biomarker
                      profiles and the broad spectrum of diseases associated with
                      cognitive decline. Beyond the Alzheimer's disease clinical
                      spectrum, current studies aim at investigating CSF
                      biomarkers to better differentiate tauopathies,
                      TDP43(Transactive response DNA binding protein 43
                      kDa)-proteinopathies and synucleinopathies.},
      keywords     = {Humans / Alzheimer Disease: diagnosis / tau Proteins:
                      cerebrospinal fluid / Prognosis / Neurodegenerative
                      Diseases: diagnosis / Biomarkers: cerebrospinal fluid /
                      Amyloid beta-Peptides: cerebrospinal fluid / Alzheimer’s
                      disease (Other) / Cerebrospinal fluid analysis (Other) /
                      Frontotemporal dementia (Other) / Lewy body dementia (Other)
                      / Neurodegenerative disease (Other)},
      cin          = {Clinical Study Team Dresden ; AG Falkenburger / AG Donix},
      ddc          = {610},
      cid          = {I:(DE-2719)1710012 / I:(DE-2719)1710008},
      pnm          = {353 - Clinical and Health Care Research (POF4-353)},
      pid          = {G:(DE-HGF)POF4-353},
      typ          = {PUB:(DE-HGF)16},
      pmc          = {pmc:PMC9718879},
      pubmed       = {pmid:35670835},
      doi          = {10.1007/s00115-022-01339-6},
      url          = {https://pub.dzne.de/record/164643},
}